Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for Tourette Syndrome
NCT04794413Phase 1Completed
- Start
- Nov 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pimavanserin in Tourette syndrome (TS). Primary endpoint: Yale Global Tic Severity Scale Total Tic Severity Score at 10 weeks. Started Nov 2018; status: completed.
02
Drugs
pimavanserin
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT04794413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794413.